You are here: Industry Insights > clinical

News List

Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections PharmaSources
October 14, 2024
Antabio’s MEM-ANT3310 is a next generation broad-spectrum antibacterial combination that has been designed to address the growing problem of antimicrobial resistance in severe hospital infections.
Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus Biotech Newswire
August 22, 2024
Touchlight announced the clinical supply of its proprietary dbDNA™ to the University of Nottingham for research and development of a next-generation DNA vaccine targeting the Zika virus.
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S. July 24, 2024
Beijing, July 24, 2024 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases
Golden Pen Award | Pharmacological Effects and Clinical Applications of Sodium Aescinate Xiaomichong
July 17, 2024
Sodium aescinate (SA) is a kind of ester-bonded triterpenoid saponin sodium salt extracted from the mature seeds of the plant Heptacodium miconioides, which belongs to the family of Hippocastanaceae.
The Pharmacological Effects and Clinical Applications of Epipremnum Aureum in the Treatment of Liver Diseases Xiaomichong
July 05, 2024
Sedum sarmentosum, also known as trailing jade plant, hanging jade plant, or dogtooth half-branch, is the dried whole plant of Sedum sarmentosum, a member of the Crassulaceae family.
Research Progress on the Pathogenesis and Clinical Diagnosis of Mycoplasma Pneumoniae Pneumonia Xiaomichong
June 26, 2024
Mycoplasmal Pneumonia Pneumonia (MPP), also known as primary atypical pneumonia or cold agglutinin-positive pneumonia, is a common respiratory disease among children caused by infection with Mycoplasmal pneumoniae (MP), which frequently occurs in school-a
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA PharmaSources
June 11, 2024
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) ap
InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma PharmaSources
May 21, 2024
The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis PharmaSources
May 16, 2024
InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
Decentralising research: Virtual clinical trials Suzanne Elvidge
May 14, 2024
Clinical trials are vital as the basis of developing safe and effective drugs, but they can be slow and expensive.